NOVN Novan Inc

Novan to Present at the Virtual Investor KOL Roundtable

Novan to Present at the Virtual Investor KOL Roundtable

- Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET

MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL Roundtable on Tuesday, October 27, 2020 at 12:00 PM ET.

Participating in the KOL Roundtable discussion will be Paula Brown Stafford, Chairman and Chief Executive Officer of Novan and Carri Geer, SVP, Chief Technology Officer of Novan. Joining the Novan Management team for the roundtable will be John Browning, MD, FAAD, FAAP, MBA​, Clinical Assistant Professor of Pediatrics and Dermatology at Baylor College of Medicine and at the University of Texas Health Science Center at San Antonio, Chief of Dermatology at the Children's Hospital of San Antonio.

A live video webcast of the KOL roundtable discussion will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

In addition to the KOL roundtable discussion, members of the management team will be available for one-on-one meetings with qualified members of the investment community. To schedule a one-on-one call with management, please submit a request through the conference website virtualinvestorco.com, or contact the conference at . For more information about the event, please visit virtualinvestorco.com.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company’s lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas

JTC Team, LLC

833-475-8247

EN
21/10/2020

Underlying

NOVNNovan Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novan Inc

 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Enters into Agreement to Sell Substantially All of its Assets, i...

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – A...

July 17, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockh...

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current focus, position...

June 5, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Focuses Strategic Direction and Announces Restructuring

Novan Focuses Strategic Direction and Announces Restructuring – Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to ...

May 31, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Reports First Quarter 2023 Financial Results and Provides Corpor...

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today...

May 15, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Novan to Report First Quarter 2023 Financial Results on May 15, 2023 DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested...

May 8, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch